The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease
Abstract
BACKGROUND: The serum tryptase level is used as a diagnostic marker in mastocytosis and is considered to reflect the burden of (neoplastic) mast cells (MC). METHODS: In the present study, serum tryptase levels were measured in patients with mastocytosis by fluoroenzyme immunoassay and compared with the extent of infiltration of the bone marrow (BM) by neoplastic MC, determined by tryptase immunohistochemistry. Sixteen patients with cutaneous mastocytosis (CM) and 43 patients with systemic mastocytosis (SM) were examined. RESULTS: In most patients with CM (defined by the absence of dense compact MC infiltrates in tryptase-stained BM sections), normal or near-normal serum tryptase levels (median 10 ng/ml, range 2-23 ng/ml) were measured. By contrast, in the vast majority of patients with SM, elevated serum tryptase levels (median 67 ng/ml) were found. In addition, there was a significant correlation between the grade of infiltration of the BM by neoplastic MC and tryptase levels in patients with SM (r = 0.8). Moreover, enzyme levels differed significantly among the groups of patients with different types of SM. The highest levels (>900 ng/ml) were detected in the patient with MC leukemia, 2 patients with slowly progressing SM and high MC burden (smoldering SM) and 1 patient with indolent SM. In contrast, in all 3 patients with isolated BM mastocytosis (no skin lesions and no signs of multiorgan involvement), serum tryptase levels were <20 ng/ml. CONCLUSIONS: In summary, our data suggest that the measurement of serum tryptase is a reliable noninvasive diagnostic approach to estimate the burden of MC in patients with mastocytosis and to distinguish between categories of disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is however correlated with disease severity since tryptase serves a B-finding if it is above 200 ng/mL (adjusted for the TPSAB1 status) [56,72].”
From Diagnostic Significance of Tryptase for Suspected Mast Cell Disorders (2023) · cites this paper as [72]
Citations
Cites
Hsu, S. M., Raine, L., & Fanger, H. (1981) · Journal of Histochemistry & Cytochemistry · doi:10.1177/29.4.6166661 · Cited by 14,075
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
Devesa, S. S., Blot, W. J., & Fraumeni, J. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10 · Cited by 2,097
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Núñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,114
Self-citationNagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S. H., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 871
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Longley, B. J., Tyrrell, L., Lu, S.-Z., Ma, Y., Langley, K., Ding, T.-G., Duffy, T. P., Jacobs, P., Tang, L. H., & Modlin, I. M. (1996) · Nature Genetics · doi:10.1038/ng0396-312 · Cited by 606
Longley, B. J., Metcalfe, D. D., Tharp, M. D., Wang, X., Tyrrell, L., Lu, S.-Z., Heitjan, D., & Ma, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1609 · Cited by 550
Travis, W. D., Li, C., Bergstralh, E. J., Yam, L. T., & Swee, R. G. (1988) · Medicine · doi:10.1097/00005792-198811000-00001 · Cited by 485
Schwartz, L. B., Sakai, K., Bradford, T. R., Ren, S., Zweiman, B., Worobec, A. S., & Metcalfe, D. D. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118337 · Cited by 371
Classification and Diagnosis of Mastocytosis: Current Status
Metcalfe, D. D. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12468882 · Cited by 344
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–207 of 207
Потапенко, В. Г., & Morozova, E. V. (2024) · Clinical oncohematology · doi:10.21320/2500-2139-2024-17-2-180-194
Nouveaux critères diagnostiques des mastocytoses : des progrès mais encore des interrogations
Arock, M. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.03.009
Cutaneous Lymphomas, Mastocytosis, and Histiocytosis
Prohić, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-66131-0_35
Livideanu, C. B., El-Samrout, C., & Gaudenzio, N. (2025) · EMC - Dermatología · doi:10.1016/s1761-2896(24)50024-3
Rüfer, A., Müllner, G., Fuchs, O., Sperr, W. R., & Hoermann, G. (2025) · Swiss Medical Weekly · doi:10.57187/s.3679
Self-citationCharacterization of a case series of Mastocytosis in a health care center in Cali, ColombiaPreprint
Sandoval, D. M., Montes, O. F. B., Zambrano-Urbano, J. L., & Gutierrez, R. G. (2021) · Research Square · doi:10.21203/rs.3.rs-939459/v1
AMICI, M. D., Taietti, I., Castagnoli, R., Bossi, G., Randazzese, S. F., Marseglia, A., Caimmi, S. M. E., & Licari, A. (2026) · Biomolecules · doi:10.3390/biom16091360
Metadata
- Authors
- Sperr, W. R., Jordan, J.-H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Horny, H.-P., & Valent, P.
- Affiliations
- University of Vienna (AT)
- Hospital Universitario Ramón y Cajal (ES)
- Universität Innsbruck (AT)
- University of Lübeck (DE)
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 128
- Issue
- 2
- Pages
- 136-141
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W2085568341
- Cited by
- 207
- References
- 33
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 11 · 2023: 18 · 2022: 6 · 2021: 15 · 2020: 7 · 2019: 8 · 2018: 14 · 2017: 5 · 2016: 7 · 2015: 12 · 2014: 18 · 2013: 6 · 2012: 8
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Archives of Allergy and Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Austrian Science Fund
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Hematology › Histiocytic Disorders and Treatments
- Keywords
- serum tryptase, mastocytosis, systemic mastocytosis, cutaneous mastocytosis, bone marrow involvement, mast cell leukemia, diagnostic biomarkers, disease classification
- MeSH terms
- Adolescent, Adult, Aged, Biopsy, Bone Marrow, Child, Female, Humans, Immunohistochemistry, Male, Mast Cells, Mastocytosis, Middle Aged, Regression Analysis, Retrospective Studies, Serine Endopeptidases, Statistics, Nonparametric, Bone Marrow Neoplasms, Tryptases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
